New technique improves T cell-based immunotherapies for solid tumors Scripps Research scientists help T cells more effectively kill solid tumors cells in vitro and in mice by tweaking an existing cancer immunotherapy.
May 01, 2024
LA JOLLA, CA Scientists from Scripps Research have enhanced an existing immunotherapy by removing the sugar coating surrounding solid tumors such as in melanoma, breast, and prostate cancer so T cells can more effectively kill tumor cells. They report in the journal Nature Biomedical Engineering on May 1, 2024, that this tweak allows T cells to get closer to their targets, which dramatically improves T-cell killing of tumor cells in mouse models.
Compared to blood tumors, solid tumors are resistant to treatment because they build a physical fort around themselves to block immune cells from entering and attacking. Part of this fort is made up of layers of sugar molecules, the outermost of which is a substance called sialic acid. To remove this sialic acid barrier, the research team fused the enzyme sialidase onto cancer therapy agents called bispecific T-cell engager (BiTE) molecules. These molecules typically work by activating a patient's own T cells against the cancer.
Solid tumors form a microenvironment around themselves that is immunosuppressive, says senior author Peng Wu, PhD, a professor in the Department of Molecular Medicine at Scripps Research. Immune cells have to enter this solid mass which is covered with sialic acid molecules that physically block T cells from infiltrating. The idea here is to introduce sialidase to the T-cell engager to chop off sialic acid from the outside of the tumor mass so that T cells have a better chance to enter.
BiTE molecules have two binding sites one that binds to molecules on tumor cell surfaces called antigens, and one that binds to the T-cell receptor complex. Several BiTE therapies are already FDA-approved, but they all target blood cancers (such as blinatumomab, which targets B-cell leukemia). However, clinical trials against solid tumors, which make up 90% of tumors, have had limited success.
All of the approved drugs for T-cell engager molecules are against blood tumors, because all of the BiTE clinical trials against solid tumors have been pretty underwhelming, says first author Zhuo Yang, PhD, who recently completed his PhD at Scripps Research under the guidance of Wu and the late Richard Lerner, MD. Were really hoping the strategy that we present here may have the potential to make a breakthrough for T-cell engaging therapies against solid tumors.
The researchers tested the fusion of sialidase to several different BiTE molecules targeting different types of cancer, including antigens associated with breast, B-cell and prostate cancers. In all cases, the addition of sialidase to create these fusion molecules improved T-cell killing in a lab dish (in vitro). In collaboration with Rutgers University, the research used fluorescent microscopy to show that these fusion molecules resulted in a much larger contact area (or immunological synapse ) between T cells and the tumor cells that enables better tumor killing.
Next, the researchers tested the fusion molecule's efficacy at treating solid tumors in mice. They found that mice that were treated with the fusion molecule had delayed tumor growth, smaller tumors, and were more likely to survive compared to mice treated with regular BiTE molecules. In one of the cancer models, treatment with the fusion molecule completely eradicated the tumors for two out of five mice.
The researchers also observed an altered microenvironment surrounding the tumor, which they credit with these improved treatment outcomes. In the presence of the fusion molecule, we have better infiltration of T cells and natural killer cells, which are good cells for killing tumors, and less accumulation of immunosuppressive cells, says Wu. So basically, the fusion molecule can convert an immunosuppressive tumor microenvironment into a more immune-permissive one.
Though the team hypothesized that adding sialidase would improve T-cell engagement, they were surprised by how much of a difference it made. By simply cutting off one single sugar thats overexpressed on the surface of tumor cells, we can have huge enhancements, says Yang. There are many sugars on the surface of tumor cells and we're only getting rid of the first layer, so we were not expecting to see such dramatic effects.
Eventually, the researchers hope that their technology will help treat human cancer patients, but first they will need to engineer the molecules to make them more suitable for humans. They also hope to inspire more cancer researchers to consider sugars when designing therapeutics.
Tumor cells have unique sugar patterns, but people rarely consider them, says Wu. Were hoping that in the future more and more people will think about sugars when they are designing therapeutic strategies.
In addition to Wu and Yang, authors of the study, Targeted desialylation and cytolysis of tumour cells by fusing a sialidase to a bispecific T-cell engager, include Yingqin Hou, Geramie Grande, Chao Wang, Yujie Shi, Jaroslav Zak, Yue Wan, Ke Qin, John R. Teijaro, and the late Richard A. Lerner of Scripps Research; and Jong Hyun Cho and Dongfang Liu of Rutgers University-New Jersey Medical School.
This work was supported by the NIH and a Cancer Research Institute/Irvington postdoctoral fellowship.
Cancer Wu, Peng
Most recent headlines
11/12/2025
Dalet, a leading provider of cloud-native, end-to-end media workflow solutions, ...
01/12/2025
L3Harris and PentenAmio formalise their teaming agreement at MilCIS 2025, streng...
01/12/2025
Artemis II is NASA's first crewed flight test of the Space Launch System rocket and Orion spacecraft. The crew, from left: Commander Reid Wiseman, Pilot Vic...
01/12/2025
IRVINE, Calif. Wooden Camera has introduced its new Accessory Collection for the Canon EOS C50. The new lineup includes a low-profile, gimbal-ready cage, expand...
01/12/2025
WASHINGTON The Federal Communications Commission has released a tentative agenda for its Dec. 18 Open Commission Meeting that will include a vote on a report an...
01/12/2025
In most years, a graph of annual local TV ad spending is about as predictable as an electrocardiogram of a reasonably healthy patient in a doctor's office. ...
01/12/2025
Many industries have seen big-ticket hardware turn into software. Switchers, though, demand a combination of real-time performance and sheer bandwidth that has ...
01/12/2025
GENEVA Shanghai will host the next quadrennial Radiocommunication Assembly (RA-27) and World Radiocommunication Conference (WRC-27), Oct. 11-Nov. 12, 2027. This...
01/12/2025
NEW YORK Just in time for Giving Tuesday tomorrow (Dec. 2), the Broadcasters Foundation of America is seeking out donations to help television and radio industr...
01/12/2025
STOCKHOLM, Sweden Net Insight CEO Crister Fritzson has informed the company's board that he will retire from the video transport and media cloud technology ...
01/12/2025
01 Dec 2025
Kyivstar and Ukrainian Ministry of Digital Transformation Select Go...
01/12/2025
The prequel to the global hit Sky Original mob crime saga, Gomorrah' is a s...
01/12/2025
Featuring Florence Welch, Red Hot Chilli Peppers' Flea, designer Bella Freud...
01/12/2025
Back to All News
A Down to Earth, All Too Relatable Hero: Cashero' Teaser ...
01/12/2025
In the rush to deliver content to every screen, many broadcasters overlook one of the most crucial steps in the workflow: format and frame rate conversion. Get ...
01/12/2025
Fox Corporation Chief Financial Officer Steve Tomsic to Participate in Upcoming ...
01/12/2025
Arvato Systems' Virtual Private Cloud (VPC) Receives BSI C5 Certification (T...
01/12/2025
Summary This short video gives you an summary of the changes in under two minutes.
--...
01/12/2025
As the festive season approaches, RT Supporting the Arts is proud to showcase a...
01/12/2025
Researchers worldwide rely on open-source technologies as the foundation of their work. To equip the community with the latest advancements in digital and physi...
01/12/2025
Festive specials of Christmas in Kilmainham presented by Marty Whelan, High Road Low Road, Callan Kicks the Year and Keys to My Life
Ring in the New Year with ...
01/12/2025
Architect and television presenter Hugh Wallace, best known to RT audiences as a long-serving judge on Home of the Year, has died at the age of 68.
In a state...
28/11/2025
Nadia Fall attends the 2025 Sundance Film Festival premiere of Brides at the Egyptian Theatre on January 24, 2025, in Park City, Utah. (Photo by Donyale West/...
28/11/2025
It's easy to ignore those little red update available badges. But when it ...
28/11/2025
WASHINGTON Federal Communications Commission has released a tentative agenda for the December Open Commission Meeting scheduled for Thursday, December 18, 2025 ...
28/11/2025
The Professional Fighters League is looking to super-serve fans of mixed martial...
28/11/2025
Fubo has released in beta on select Roku devices a new feature that lets users display up to four simultaneous streams at once....
28/11/2025
The WNBA playoffs and Week 4 of the NFL regular season highlight the list of live sports events airing on television this weekend....
28/11/2025
The 32nd class of honorees to the B+C Hall of Fame took to the stage at New York's Ziegfeld Ballroom on September 26 for a gala induction event. Click below...
28/11/2025
We hold in our hands the very last Next Text for Next TV, the weekly back-and-fo...
28/11/2025
DirecTV said it made a deal with EchoStar to buy EchoStar's video businesses, including satellite-TV provider Dish TV and virtual MVPD Sling TV, for $1 plus...
28/11/2025
The Broadcasting+Cable Hall of Fame, the premier industry event paying tribute to the influencers, innovators and shining lights of broadcast, cable and streami...
28/11/2025
Friday 28 November 2025
Sky Sports x Slawn drop limited-edition football jersey...
28/11/2025
Rohde & Schwarz shows resilience in a challenging environment, revenue exceeds t...
28/11/2025
Unwrapped: The Toy Show Appeal - airing this Sunday on RT One and RT Player- s...
27/11/2025
LONDON Vizrt has added several AI-driven advanced features offering improved speed, intelligence and accuracy in the newest version of its media asset managemen...
27/11/2025
Prime Video has launched AI-powered video season recaps in a beta version for select English-language Prime Original series in the U.S., a move Amazon is callin...
27/11/2025
Back to All News
Netflix's Raat Akeli Hai: The Bansal Murders Marks a Grand...
27/11/2025
27 Nov 2025
GSMA brings M360 Eurasia 2026 to Samarkand in partnership with VEON...
27/11/2025
Tahar Rahim and Izuka Hoyle star in the gripping six-part Sky Original from Acad...
27/11/2025
Thursday 27 November 2025
Sky Arts Reveals the Nation's Greatest Basslines - and Queen Reign Supreme
The UK's most iconic basslines have been revealed...
27/11/2025
Back to All News
Stranger Things 5': Prepare for One Last Adventure With O...
27/11/2025
The media industry has a paradox at its core. It's an industry built on light, color and imagination, yet behind the scenes, it's powered by one of the ...
27/11/2025
Rating reflects rating progress across areas including policies, diversity & inclusion, health & safety and Net Zero leadership
Winchester, UK, 27 November 202...
27/11/2025
What are the industry standards for Retail Media? Kathryn explains that certification is based on the IAB Europe Retail Media Measurement Standards and the IAB ...
27/11/2025
World champion boxer and Irish sporting icon Katie Taylor will be in studio this...
27/11/2025
Roblox, one of the world's most popular online gaming platforms for primary ...
27/11/2025
Black Friday is leveling up. Get ready to score one of the biggest deals of the season - 50% off the first three months of a new GeForce NOW Ultimate membership...
26/11/2025
SVG Sit-Down: Prime Video EP Mike Muriano Previews Massive Black Friday Slate Fe...
New technique improves T cell-based immunotherapies for solid tumors Scripps Research scientists help T cells more effectively kill solid tumors cells in vitro and in mice by tweaking an existing cancer immunotherapy.
